Surbhi Sarna is a Group Partner at YC. She was the founder and former CEO of nVision Medical, which developed a first-in-kind microcatheter for the detection of ovarian cancer. After raising $17M in venture funding, completing three clinical trials, and obtaining two first-in-class FDA approvals, nVision was acquired by Boston Scientific (NYSE: BSX) for $275M, more than 15X money-in. Surbhi stayed at Boston Scientific for two years, running the 150+ person commercial organization in preparation for launch. She sits on both private and public company boards.